The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Tamir brings more than 20 years of experience in the medical technology sector
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Aims to boost speed & precision in patient care
Subscribe To Our Newsletter & Stay Updated
